05 in multivariate logistic regression was considered statistical significance. Statistical analysis was performed with the SPSS software package, version selleck chem 11.5 (SPSS Inc., Chicago, IL, USA).3. Results3.1. Patient CharacteristicsDuring the study period, 1302 specimens of BC grew SLO, 504 were MSSA, 458 were MRSA, and 340 were coagulase-negative Staphylococcus. A total 458 blood MRSA specimens were isolated from 435 patients. After exclusion of patients who died of unrelenting sepsis on the day of admission, those who were discharged from our emergency department on the same visiting day, those who had polymicrobial bacteremia or those who had endocarditis, or those did not received a GP during hospitalization, 339 patients with MRSAB were included for analyses.
The mean elapsed time from sampling blood for culture to SLO was 22.8 �� 8.0h. Prior to starting GP therapies (teicoplanin 83.2% and vancomycin 16.8%) for MRSAB, 245 of the included patients received treatment with antibiotics other than a GP (81.6% received ��-lactams, 18.3% quinolones, and 10.2% aminoglycosides). A total of 56 (16.5%) patients died within 14 days after SBFC, and 38 (11.2) patients died due to MRSA infection. There was no significant difference in overall or infection-related mortality rates among patients received treatment with teicoplanin or vancomycin (16.3% versus 17.5%; P = 0.82 and 10.6% versus 14.0%; P = 0.46, resp.).3.2. Factors Associated with Timing of Administration of Glycopeptide TherapyUnivariate analyses of initial GP therapy stratified according to the timing of preliminary BC indicating SLO growth were summarized in Table 1.
The significantly different variables between different groups of GP therapy stratified accordingly to the timing of preliminary BC indicating SLO growth included male patients (P = 0.03), uremia requiring hemodialysis (P = 0.05), admission to ICU Drug_discovery (P = 0.03), and APACHE II score > 15 (P < 0.01). It suggested that clinical severity was the clinicians' main concern and indication for starting GP therapy.Table 1Factors affecting when GP therapy was initiated in patients with MRSA bacteremia.3.3. Predicting 14-Day Mortality Associated with MRSABUnivariate analyses for patients with MRSAB who died within 14 days (n = 56) and for survivors (n = 283) were summarized in Table 2. Significantly different variables included diabetic mellitus (53.6% versus 37.8%; P = 0.04), APACHE II score > 15 (23.2% versus 10.9%; P = 0.03), pneumonia (35.7% versus 10.9%; P < 0.01), and catheter-related infection (1.8% versus 13.8%; P < 0.01).
No related posts.